Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Travelan · IMM-124E

Other · developed by Immuron

Phase 2 Most advanced trial (none active)

IMRN Developer

1 Registered trials

What is Travelan?

Travelan (IMM-124E) is administered orally at 1200 mg once daily. It is studied for the treatment of travelers' diarrhea and infectious diarrhea.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: IMM-124E
Drug type: Other
Therapy area: Gastroenterology
Developer: Immuron Ltd. (IMRN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05933525	Phase 2	Diarrhea	Completed	IMRN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DiarrheaInfectious DiarrheaTravelers Diarrhea

More from Immuron

IMM-124E Phase 2 IMM-529 Phase 1/2

Sources

ClinicalTrials.gov NCT05933525

Updated Oct 3, 2026. Something wrong or missing? Report it on the IMRN page.

Follow IMRN, the company behind Travelan

See IMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IMRN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z